Encenicline

Encenicline
Systematic (IUPAC) name
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
Identifiers
CAS Number 550999-75-2
ATC code None
PubChem CID 46196517
ChemSpider 28637768
ChEMBL CHEMBL2151572
Chemical data
Formula C16H17ClN2OS
Molar mass 320.837 g/mol

Encenicline (INN, USAN) (code names EVP-6124, MT-4666) is a selective partial agonist of the α7 nicotinic receptor, and is in phase III clinical trials for the treatment of cognitive impairment in schizophrenia.[1][2]

See also

References

  1. Melville, Nancy A. "Novel Drug Targets 'Huge Unmet Need' in Schizophrenia". Medscape. Retrieved 13 April 2015.
  2. Barbier, AJ (2015-02-01). "Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies". Clinical Therapeutics 37 (2): 311–24. doi:10.1016/j.clinthera.2014.09.013. PMID 25438724.

External links



This article is issued from Wikipedia - version of the Thursday, December 17, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.